By Z. Gunnar. Westwood College of Technology.
Were the groups similar at baseline in terms of prognostic factors? Were outcome assessors blinded to the treatment allocation? Was the patient kept unaware of the treatment received? Did the article include an intention-to-treat analysis or provide the data needed to calculate it (that is discount female cialis 10 mg on-line women's health kilojoule counter, the number assigned to each group buy female cialis 10 mg with visa women health center, number of subjects who finished in each group, and their results)? Did the article report attrition, crossovers, adherence, and contamination? Topical calcineurin inhibitors Page 54 of 74 Final Report Drug Effectiveness Review Project 11. Is there important differential loss to follow-up or overall high loss to follow-up? How similar is the population to the population to whom the intervention would be applied? What was the funding source and role of funder in the study? Was the selection of patients for inclusion nonbiased; that is, was any group of patients systematically excluded? Is there important differential loss to followup or overall high loss to followup? Was there a clear description of the techniques used to identify the events? Was there nonbiased and accurate ascertainment of events (independent ascertainers; validation of ascertainment technique)? Were potential confounding variables and risk factors identified and examined using acceptable statistical techniques? Was the duration of follow-up reasonable timing for investigated events? How similar is the population to the population to whom the intervention would be applied? What was the funding source and role of funder in the study? Current methods of the US Preventive Services Task Force: a review of the process. Topical calcineurin inhibitors Page 55 of 74 Final Report Drug Effectiveness Review Project 3. A critical review of reviews on the treatment of chronic low back pain. Validation of an index of the quality of review articles. Topical calcineurin inhibitors Page 56 of 74 Final Report Drug Effectiveness Review Project Appendix C. Excluded studies Reasons for exclusion: 1=Foreign language 2= wrong outcome 3= wrong intervention 4=wrong population 5=wrong publication type 6=wrong study design 7= insufficient duration Excluded publications Code Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Ashcroft D, Chen L-C, Garside R, Stein K, Williams H. Pimecrolimus cream 1% is effective, well-tolerated and safe in infants and children with atopic eczema of the face. Journal of the European Academy 5 of Dermatology & Venereology. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized 6 controlled clinical trials programme. The efficacy and safety of tacrolimus ointment: a clinical review.
Various dosage forms may exist for the same compound purchase 10mg female cialis overnight delivery menstrual bloating treatment, since different medical conditions may warrant different routes of administration buy female cialis 10mg low price womens health week. Triptans Page 56 of 80 Final Report Update 4 Drug Effectiveness Review Project Dose-response relationship: The relationship between the quantity of treatment given and its effect on outcome. In meta-analysis, dose-response relationships can be investigated using meta- regression. Double-blind: The process of preventing those involved in a trial from knowing to which comparison group a particular participant belongs. While double-blind is a frequently used term in trials, its meaning can vary to include blinding of patients, caregivers, investigators, or other study staff. Double-dummy: The use of two placebos in a trial that match the active interventions when they vary in appearance or method of administrations (for example, when an oral agent is compared with an injectable agent). Effectiveness: The extent to which a specific intervention used under ordinary circumstances does what it is intended to do. Effectiveness outcomes: Outcomes that are generally important to patients and caregivers, such as quality of life, responder rates, number and length of hospitalizations, and ability to work. Data on effectiveness outcomes usually comes from longer-term studies of a “real-world” population. Effect size/estimate of effect: The amount of change in a condition or symptom because of a treatment (compared to not receiving the treatment). It is commonly expressed as a risk ratio (relative risk), odds ratio, or difference in risk. Efficacy: The extent to which an intervention produces a beneficial result under ideal conditions in a selected and controlled population. Equivalence level: The amount which an outcome from two treatments can differ but still be considered equivalent, as in an equivalence trial, or the amount which an outcome from treatment A can be worse than that of treatment B but still be considered noninferior, as in a noninferiority trial. Equivalence trial: A trial designed to determine whether the response to two or more treatments differs by an amount that is clinically unimportant. This lack of clinical importance is usually demonstrated by showing that the true treatment difference is likely to lie between a lower and an upper equivalence level of clinically acceptable differences. Exclusion criteria: The criteria, or standards, set out before a study or review. Exclusion criteria are used to determine whether a person should participate in a research study or whether an individual study should be excluded in a systematic review. Exclusion criteria may include age, previous treatments, and other medical conditions. External validity: The extent to which results provide a correct basis for generalizations to other circumstances. For instance, a meta-analysis of trials of elderly patients may not be generalizable to children. Studies are assumed to be measuring the same overall effect. Fixed-dose combination product: A formulation of two or more active ingredients combined in a single dosage form available in certain fixed doses. Triptans Page 57 of 80 Final Report Update 4 Drug Effectiveness Review Project Forest plot: A graphical representation of the individual results of each study included in a meta- analysis and the combined result of the meta-analysis. The plot allows viewers to see the heterogeneity among the results of the studies. The results of individual studies are shown as squares centered on each study’s point estimate. A horizontal line runs through each square to show each study’s confidence interval—usually, but not always, a 95% confidence interval. The overall estimate from the meta-analysis and its confidence interval are represented as a diamond. The center of the diamond is at the pooled point estimate, and its horizontal tips show the confidence interval.
A 48 week buy discount female cialis 20 mg on line womens health group lafayette co, randomized order 20 mg female cialis with mastercard womens health articles, open label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. Early vs deferred HAART switch in heavily pre-treated HIV patients with low viral load level and stable CD4 cell count. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with HIV infection and long-lasting viral suppression. Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial. Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, ral- tegravir, etravirine. Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). A Switch in Therapy to a Reverse Transcriptase Inhibitor Sparing Combination of Lopinavir/Ritonavir and Raltegravir in Virologically Suppressed HIV-infected Patients: A Pilot Randomized Trial to Assess Efficacy and Safety Profile: The KITE Study. AIDS Res Hum Retroviruses 2012, 28:1196- 2062012 Feb 26. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in HIV infection. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. Saquinavir/ritonavir monotherapy as a new nucleoside-sparing main- tenance strategy in long-term virologically suppressed HIV-infected patients. High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir. Switching to dual therapy (atazanavir/ritonavir+ lamivudine) vs. No evidence for evolution of genotypic resistance after three years of treatment with darunavir/ritonavir, with or without nucleoside analogues. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucle- osides for maintenance therapy of HIV. AIDS 2008;22: Pulido F, Delgado R, Pérez-Valero I, et al. Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtric- itabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ ANRS143 ran- domised non-inferiority trial. Lancet 2014, Aug 5, pub ahead of print Rasmussen TA, Jensen D, Tolstrup M, et al. Comparison of bone and renal effects in HIV-infected adults switch- ing to abacavir or tenofovir based therapy in a randomized trial. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: ADAM study. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients. Antivir Ther 2014, 19:117-23 Ribera E, Larrousse M, Curran A, et al. Impact of switching from zidovudine/lamivudine to tenofovir/emtric- itabine on lipoatrophy: the RECOMB study. Improvements in subcutaneous fat, lipid profile, and parameters of mito- chondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). Class-sparing regimens for initial treatment of HIV-1 infection.
Antiemetic efficacy and pharmacokinetic analyses of the serotonin antagonist ondansetron (GR 38032F) during multiple-day chemotherapy with cisplatin 2 prior to autologous bone marrow transplantation order female cialis 10 mg without prescription breast cancer jewelry. Le Bonniec M cheap 20mg female cialis visa breast cancer awareness month 2014, Madelaine I, Dieras V, Extra JM, Romain D, Marty M. Results of a single blinded randomized study with cross-over of granisetron and 2 standard anti-emetics in the prophylaxis of chemotherapy-induced emesis. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer 2 with cyclophosphamide, methotrexate, and fluorouracil. Randomized, Double-Blind Trial of Dolasetron Versus Droperidol for Prophylaxis of Postoperative Nausea and 2 Vomiting in Patients Undergoing TRAM Flap Breast Reconstruction Surgery. The efficacy of ondansetron versus tropisetron as antiemetics in the postoperatory of laparoscopic surgery. The effect of ondansetron and meocloprarnide was compared in the prevention of emesis. Postoperative nausea and vomiting in diagnostic gynaecological laparoscopic procedures: Comparison of the efficacy of the combination of dexamethasone and metoclopramide 2 with that of dexamethasone and ondansetron. Antiemetics Page 101 of 136 Final Report Update 1 Drug Effectiveness Review Project Exclusion Excluded Studies code # Manolas G, Alexopoulos CG, Vaslamatzis M, Papacharalambous S, Papachristodoulou A, Xynogalos S. A comparative study of the effectiveness of ondansetron vs hig dose metoclopramide + dexamethasone in the anti- 2 emesis during high dose cisplatinum II (CDDP) chemotherapy. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i. Intrathecal fentanyl is superior to intravenous ondansetron for the prevention of perioperative nausea during 2 cesarean delivery with spinal anesthesia. Manusirivithaya S, Isariyodom P, Chareoniam V, Sungsab D. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide- 2 dexamethasone-lorazepam in the control of cisplatin induced emesis. A singled-blind randomized comparator study with crossover of granisetron, a selective 5-HT3 antagonist versus standard anti-emetics in the 2 prophyhlaxis og chemotherapy-induced emesis. Double-blind randomized trial of the anti-emetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin 2 and cyclophosphamide. Double-blind randomised trial of the anti-emetic efficacy and safety of ondansetron and metoclopramide in advance breast cancer patients treated with epirubicin 2 and cyclophosphamide. Marschner NW, Adler M, Nagel GA, Christmann D, Fenzl E, Upadhyaya B. Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated 2 with Epirubicin and cyclophosphamide. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus 2 dexamethasone in the treatment of cytostatic-induced emesis. A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cystostatic-induced 2 emesis. Curative efficacy of ondansetron against nausea and emesis induced by anticancer drugs: A study versus 2 metoclopramide. Antiemetics Page 102 of 136 Final Report Update 1 Drug Effectiveness Review Project Exclusion Excluded Studies code # Marty M, Paillarse JM, the French Study G. Efficacy of ondansetron (ONC) and metoclopramide (MCP) as an intervention treatment in patients 2 experiencing emesis. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose 2 metoclopramide in the control of cisplatin-induced emesis. Mehta NH, Reed CM, Kuhlman C, Weinstein HJ, Parsons SK. Controlling conditioning-related emesis in children undergoing bone marrow 2 transplantation. Randomised double-blind comparison of ondansetron and droperidol to prevent postoperative nausea 2 and vomiting associated with patient-controlled analgesia. Prevention of chemotherapy- induced emesis with granisetron in children with malignant diseases. Ondansetron is not superior to moderate dose metoclopramide in the prevention of post-operative nausea 2 and vomiting after minor gynaecological surgery.
8 of 10 - Review by Z. Gunnar
Votes: 83 votes
Total customer reviews: 83